Este es un evento pasado. El registro está cerrado. Ver más eventos de AmCham Taipei

Detalles del Evento

Liver disease has been seen as the national disease for many years. Liver disease management has been identified as government’s public health top priority. Hepatitis B virus (HBV) and Hepatitis C virus (HCV) are the 2 key risk factors for liver cancer. Government, physicians, public health experts and pharmaceutical companies have been working together to achieve reducing HBV, HCV and liver cancer for many years.

In the past 30 years, 2 key milestone have been achieved. Vice President Chen was invited by WHO to share Taiwan successful experience on reducing HBV prevalence rate from around 20% to 1% through the HBV vaccination program implemented in 1980. Unlike HBV, HCV has no vaccine, fortunately, with pharmaceutical R&D, new HCV drugs launched few years ago, which can achieve over 90% cure rate. Government reimbursement HCV drugs in 2017 which is another key milestone of combating liver disease in Taiwan.

How can government, physicians, public health experts and pharmaceutical industry to work even closer to eliminate liver disease in Taiwan? We would like to learn the 1 million dollar answer from 2 respectful speakers, Dr. DS Chen, the academicians of Academic Sinica, and Dr. Jasmine Pwu, the Director of National HCV office.


  • D

    Dr. Ding-Shinn Chen

    Academician of Academic Sinica 中央研究院陳定信院士

    Leer Biografía
  • D

    Dr. Raoh-Fang (Jasmine) Pwu

    Director, National Hepatitis C Program Office, Minister of Health and Welfare, Taiwan 衛生福利部 國家C型肝炎旗艦計畫辦公室主任 蒲若芳博士

    Leer Biografía




AmCham Taipei member representatives only (Lunch Included)

TW$ 1,400
Member Guests / Non-member

(Lunch Included)

TW$ 2,000

Ticket Refund Policy

To cancel without penalty, written cancellation must be received by AmCham 24 hours before the event, or else full Price of the event will be charged. Expense for any guests invited by an AmCham member will be billed to the member’s account directly.